Skip to main content
SpringerLink
Log in

Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients

  • Original Article
  • Published:
Pathology & Oncology Research

Abstract

Hypermethylation is epigenetic alteration, well known for gene silencing. CHD1 gene is known as invasion and tumor suppressor gene, decreased expression due to hypermethylation could promote tumor cell invasion and metastasis. Present study designed to investigate the CDH1 gene promoter hypermethylation status by methylation specific polymerase chain reaction in 100 newly diagnosed gastric cancer patients. 53% of hypermethylation was observed in DNA extracted from blood in Gastric cancer patients while 66% was observed in serum based DNA. Significant differences in CDH1gene promoter hypermethylation was observed in serum based DNA extracted from Gastric cancer patients. Patients in early stage (I & II) vs advanced stage (III & IV), distant organ metastases vs no metastases had 60% vs 7% and 42% 24% of CDH1 promoter hypermethylation in serum DNA (p = 0.006, 0.001) respectively. Patients who were with lymph node invasion, loss of appetite, loss of weight had 55%, 47%, 61% CDH1 gene promoter hypermethylation compare to who were not with lymph node invasion, loss of appetite, loss of weight had 11%, 19%, 5% of hypermethylation and these differences was found to be significant. Strong association was observed with overall median survival of patients (p < 0.0001). Patients who had CDH1 gene promoter hypermethylation in serum based DNA showed poor overall median survival (14.3 months) and unmethylated patients had better overall median survival (33.2 months). CDH1 hypermethylation status was found to be associated with advancement of disease, distant organ metastases and lymph node invasion in Gastric cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29

    Google Scholar 

  2. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF (2000) A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19(43):4947–4953

    Article  CAS  Google Scholar 

  3. Yousuf A, Bhat MY, Pandith AA, Afroze D, Khan NP, Alam K, Shah P, Shah MA, Mudassar S (2014) MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell Oncol 37:245–252

    Article  CAS  Google Scholar 

  4. Goffin J, Eisenhauer E (2002) DNA methyltransferase inhibitors—state of the art. Ann Oncol 13:1699–1716

    Article  CAS  Google Scholar 

  5. Baylin SB, Belinsky SA, Herman JG (2000) Aberrant methylation of gene promoters in cancer. Concepts, misconcepts and promise. J Natl Cancer Inst 92:1460–1461

    Article  CAS  Google Scholar 

  6. Van RF (2014) Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer 14:121–134

    Article  Google Scholar 

  7. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Alexiou D, Kalahanis N et al (1998) Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res 18:4177–4180

    CAS  PubMed  Google Scholar 

  8. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P (2009) E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 69:2050–2056

    Article  CAS  Google Scholar 

  9. Galanter JM, Christopher RG, Sam SO, Torgerson D, Pino-Yanes M, Thakur N et al (2015) Methylation analysis reveals fundamental differences between ethnicity and genetic ancestry. Bio Rxiv. https://doi.org/10.1101/036822

  10. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS (2003) Aberrant CpG Island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 163:1551–1556

    Article  CAS  Google Scholar 

  11. Choi IS, Wu TT (2005) Epigenetic alterations in gastric Carcinogenesis. Cell Res 15:247–254

    Article  CAS  Google Scholar 

  12. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D (1996) Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2(9):1035–1037

    Article  CAS  Google Scholar 

  13. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J (1998) Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 58:1405–1407

    CAS  PubMed  Google Scholar 

  14. Kopreski MS, Benko FA, Borys DJ, Khan A, Kwee CM, McGarrity TJ et al (1998) Mutated KRAS DNA in plasma as a marker in early colorectal neoplasia. Proc Am Soc Clin Oncol 17:269

  15. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF (2002) Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8:1761–1766

    CAS  PubMed  Google Scholar 

  16. Rashid H, Alam K, Afroze D, Yousuf A, Banday M, Kawoosa F (2016) Hypermethylation status of E-Cadherin gene in gastric cancer patients in a high incidence area. APJCP 17(6):2757

    PubMed  Google Scholar 

  17. Tamura G, Yin J, Wang S, Fleisher AS, Abraham JM, Kong D (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92:569–573

    Article  CAS  Google Scholar 

  18. Benton G, Crooke E, George J (2009) Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J 23:3884–3895

    Article  CAS  Google Scholar 

  19. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY (2001) Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20:3814–3823

    Article  CAS  Google Scholar 

  20. Liu J, Sun X, qin S, Wang H, Ning D, Li Y et al (2016) CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol Lett 11:2635–2643

    Article  CAS  Google Scholar 

  21. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, Rogatto SR (2006) CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6:48

    Article  Google Scholar 

  22. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163(4):1371–1378

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Author thanks to all the study subjects that participated in this study.

Author information

Authors and Affiliations

  1. Physical examination center, Gansu Gem Flower Hospital, Lanzhou petrochemical general hospital, Lanzhou, 730060, Gansu, China

    Zhi Li

  2. Medical section, Gansu Gem Flower Hospital, Lanzhou petrochemical general hospital, Lanzhou, 730060, Gansu, China

    Zhiqiang Guo

Authors
  1. Zhi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiqiang Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhiqiang Guo.

Ethics declarations

Conflict of Interest

None.

ZL: Conducting experiment, Data collection and writing.

ZG: Concept, study design, analysis of data, drafting of manuscript and approval for final draft.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Guo, Z. Comparison of CDH1 Gene Hypermethylation Status in Blood and Serum among Gastric Cancer Patients. Pathol. Oncol. Res. 26, 1057–1062 (2020). https://doi.org/10.1007/s12253-019-00658-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-019-00658-5

Keywords

Search

Navigation